Cycloserine (Cs) is an anti-mycobacterial oral drug recommended by the World Health Organization (WHO) for the treatment of MDR-TB. No WHO-endorsed phenotypic drug-susceptibility testing is currently possible given that insufficient evidence existed in 2018 to set any critical concentration (CC). WHO would like to update its 2018 systematic review given that several studies have been published recently that might allow for a CC to be defined.
To support this process, WHO is issuing a public call for data, appealing to national TB programmes, implementers, industry, researchers, and other agencies to provide suitable evidence on cycloserine minimal inhibitory concentrations (MICs).
The data will be essential to facilitate the process of WHO policy updates, scheduled for September of 2023. Please send relevant data by 31st July 2023, to Alexei Korobitsyn at korobitsyna@who.int
Please see below more information on the parameters of the data:
1. At least three concentrations were tested using the proportion method with a critical proportion of 1% using LJ, 7H10, 7H11 or MGIT.
2. Concentrations tested must be clearly defined (i.e. to assess potential truncations of the MIC results).
3. The number of isolates tested at each concentration are provided (i.e. to evaluate the shape of the MIC distributions and determine the mode of the distributions).
4. At least 5 unique isolates were tested.
5. If available, whole genome sequencing data or other genotypic information about mutations in Cs resistance genes.